NAD+ Dosing: Ranges by Route, Protocols, and Safety

August 28, 2026
Hands preparing IV NAD+ infusion in clinic

Most adults starting NAD+ therapy will see one of three approaches: IV sessions running 250 to 500 mg per visit (with intensive protocols reaching 1,500 mg under supervision), subcutaneous or intramuscular injections of 25 to 200 mg two to three times weekly, or oral NMN/NR precursors at 250 to 1,000 mg daily. The clinically common pattern pairs an IV loading phase for rapid repletion with SubQ or oral dosing for maintenance. Higher-dose protocols require clinician oversight.

TL;DR:

  • IV NAD+ doses commonly start at 250 mg weekly, with intensive protocols reaching up to 1,500 mg infused over several hours under clinical supervision.
  • Subcutaneous injections typically begin at 25 to 50 mg, titrate to 100-200 mg two to three times weekly, and can be self-administered quickly at home.
  • Oral NMN or NR doses range from 250 to 1,000 mg daily, with measurable NAD+ increases usually seen within 1 to 2 weeks and effects in 4 to 8 weeks.
  • Reconstituted NAD+ vials require accurate dilution calculations for proper dosing, with more dilute mixes causing less injection-site pain but larger volumes.
  • The choice of route depends on your goals, budget, time availability, and medical history, with personalized protocols adjusting doses based on individual response.

Table of Contents

NAD+ Dosing Chart: Ranges, Frequency, and Session Notes by Route

Before choosing a protocol, it helps to see the routes side by side. Each delivery method trades speed and bioavailability against convenience and cost, and the right choice depends on what you’re treating and how much clinic time you can commit to.

  • IV infusion, entry level: 250 mg per session, typically once weekly during a loading phase, infused over 1 to 3 hours.
  • IV infusion, standard: 250 to 500 mg per session, weekly or biweekly, infused over 2 to 4 hours to manage rate-dependent side effects.
  • IV infusion, high/intensive: 500 to 1,500 mg per session, used in supervised clinic protocols for neurological or addiction recovery support, often infused over 4 or more hours.
  • Subcutaneous injection: 25 to 50 mg to start, titrating to a maintenance range of 100 to 200 mg, 2 to 3 times per week, self-administered at home in under a minute.
  • Intramuscular injection: Similar mg ranges to SubQ but delivered into muscle tissue, sometimes chosen when a clinic wants faster absorption without IV access.
  • Oral NMN: 250 to 1,000 mg daily, taken as a single morning dose or split into two doses.
  • Oral NR: 250 to 600 mg daily, generally dosed once in the morning.

The IV route delivers the fastest, most direct increase in circulating NAD+, but it demands clinic time and, for higher doses, several hours in a chair. SubQ and IM dosing shift that burden to five minutes at your kitchen counter, at the cost of somewhat lower peak bioavailability. Oral precursors ask the least of your schedule and wallet but take the longest to show measurable change. If you’re trying to work out mg-per-mL math for a SubQ vial, the reconstitution section below walks through it step by step.

Route-by-Route Dosing: IV, SubQ, IM, and Oral NMN/NR

Each delivery method carries its own dosing logic, and the differences aren’t cosmetic. They reflect how fast NAD+ enters your bloodstream and how your body tolerates it getting there.

IV NAD+ dosing

Clinic-based IV protocols commonly start at 250 mg per session for a first-time patient, then move to a standard range of 250 to 500 mg for ongoing wellness support. Intensive protocols used in neurology or addiction recovery settings push to 500 to 1,500 mg per session, always under direct clinical supervision.

Diagram of IV NAD+ dose ranges vs infusion duration

Infusion rate matters more than the total dose for how a session feels. Slower infusions meaningfully cut down on the nausea, flushing, and chest tightness that show up when NAD+ enters the blood too quickly. A 250 mg dose over 60 minutes tends to feel very different from the same dose over 20. That’s why higher-dose sessions, especially anything above 750 mg, commonly run 3 to 6 hours.

Loading schedules vary by goal. A common wellness pattern is one IV session weekly for 3 to 4 weeks, then tapering to monthly or quarterly maintenance infusions. Intensive protocols may run daily IV sessions for 7 to 10 days before stepping down.

Subcutaneous NAD+ dosing

SubQ dosing is the workhorse of at-home maintenance. Most protocols start at 25 to 50 mg per injection and titrate upward as tolerated, landing at a maintenance dose of 100 to 200 mg, given 2 to 3 times per week.

Hands administering subcutaneous NAD+ injection

Injection-site pain is common and expected at this concentration, not a sign something’s wrong. Diluting the reconstituted solution, injecting slowly over 10 to 15 seconds, and rotating sites (abdomen, thigh, upper arm) all reduce the sting. Lower-concentration mixes, meaning more diluent per milligram of NAD+, generally hurt less than a concentrated shot squeezed into a small volume.

Intramuscular NAD+ dosing

IM dosing uses similar milligram ranges to SubQ but places the solution into muscle tissue rather than the fat layer beneath the skin. Some clinics prefer IM for slightly faster absorption or when a patient has very little subcutaneous fat to inject into. The trade-off is a deeper needle and, for some people, more next-day soreness at the site compared to SubQ.

Oral NMN and NR dosing

Oral precursors are the maintenance backbone for most long-term protocols. Human studies show NMN doses of 250 to 1,000 mg daily reliably raise blood NAD+ metabolites, while NR is typically dosed at 250 to 600 mg daily, with 300 mg being a commonly studied amount. Measurable increases in NAD+ metabolites generally appear within 1 to 2 weeks of consistent daily dosing, though subjective energy or cognitive effects often take 4 to 8 weeks to become noticeable.

Precursors are preferred for oral use over NAD+ itself because intact NAD+ molecules break down significantly in the digestive tract before absorption. NMN and NR use dedicated transport pathways that get them into cells more efficiently, where your body then converts them into NAD+.

  1. Start NMN at 250 mg or NR at 300 mg daily for the first two weeks.
  2. Increase to the higher end of the range (NMN 500 to 1,000 mg, NR up to 600 mg) if tolerated and if you’re not seeing the response you want.
  3. Reassess after 6 to 8 weeks with your clinician before adjusting further.

Pro Tip: Take oral NMN or NR with a small amount of food if you notice mild stomach upset. It doesn’t reduce absorption meaningfully but takes the edge off nausea for people with sensitive stomachs.

How to Read NAD+ Vial Math and Reconstitution

Vial labels list total milligrams, not concentration, which is where most at-home dosing errors happen. A 500 mg vial reconstituted with 5 mL of bacteriostatic water gives you 100 mg per mL. That’s the number you actually need for your syringe.

  • Basic formula: total mg in vial ÷ mL of diluent added = mg per mL.
  • Example: 500 mg vial + 5 mL BAC water = 100 mg/mL. Drawing 1 mL delivers 100 mg.
  • Converting to units: a standard U-100 insulin syringe holds 100 units per mL. At 100 mg/mL, each unit equals 1 mg, so a 50 mg dose means drawing to the 50-unit mark.
  • Different dilution example: if you reconstitute that same 500 mg vial with 10 mL instead of 5 mL, you get 50 mg/mL, so a 50 mg dose now requires drawing 1 full mL, or 100 units.
  • Lower concentration, less pain: many patients find that a more dilute mix (using more BAC water) reduces injection-site stinging, even though it means a slightly larger injection volume.

Lyophilized (freeze-dried) NAD+ powder is stable at refrigerated or room temperature for extended periods before mixing. Once reconstituted with water, it becomes far less stable and should be refrigerated and used within the window your pharmacy specifies, generally days to a few weeks depending on the compounding pharmacy’s stability data. Never use a reconstituted vial that’s changed color or developed particulates.

How to Choose a Route and Build Your NAD+ Protocol

The right protocol depends on what you’re actually trying to accomplish, not on what’s trending. A decision framework beats guessing.

  1. Define the goal first. Rapid repletion (post-illness fatigue, acute cognitive fog) points toward IV loading. General maintenance points toward SubQ or oral dosing from the start.
  2. Check the clinical indication. Neurological or addiction-recovery protocols involve higher doses and tighter supervision than general wellness use.
  3. Set a realistic budget. IV sessions cost more per visit than home-administered SubQ injections or a monthly oral supply, and the gap compounds over months of maintenance.
  4. Weigh time commitment. A 3 to 6 hour IV session weekly isn’t sustainable for most working adults long term, which is part of why maintenance almost always shifts to SubQ or oral.
  5. Factor in prior reactions. If you’ve had infusion reactions or significant injection-site pain before, that history should shape the starting dose and route your clinician recommends.

A common hybrid protocol looks like this: 3 to 5 IV loading sessions at 250 to 500 mg each over 3 to 4 weeks, followed by SubQ maintenance at 100 mg twice weekly, plus a daily oral NMN dose of 500 mg to sustain levels between injections. This layered approach gets the fast initial repletion of IV without locking you into weekly clinic visits indefinitely.

Before starting, ask your prescribing clinician: What’s the starting dose and how will we titrate it? What does a normal versus concerning reaction look like? How often will we reassess and adjust? And critically, does anything in my medical history or current medications change this plan?

Side Effects, Contraindications, and Monitoring

NAD+ therapy carries a predictable side effect profile once you know what drives it, and most of it comes down to how fast the dose enters your system.

  • Common IV-related effects: flushing, mild nausea, and a tight or heavy feeling in the chest, almost always tied to infusion speed rather than total dose.
  • Injection-site pain: expected with SubQ and IM dosing, mitigated by dilution, slow injection technique, and rotating sites.
  • Rate management: if symptoms appear mid-infusion, slowing the drip resolves most reactions within minutes.
  • Contraindications: active cancer, pregnancy, concurrent use of PARP inhibitors, and a history of severe infusion reactions.

A meaningful gap remains in the research: there are few direct head-to-head studies comparing IV, SubQ, and oral NAD+ pharmacokinetics, and long-term safety data beyond about 12 weeks is still limited for many protocols. That gap is exactly why ongoing clinician oversight matters more than following a fixed schedule blindly.

Seek immediate medical attention for chest pain that doesn’t resolve when infusion slows, difficulty breathing, or signs of an allergic reaction such as hives or facial swelling. Routine monitoring, meaning regular check-ins with your prescribing clinician, catches most issues well before they become urgent.

Example NAD+ Protocols by Goal

Seeing how doses translate into real schedules makes the abstract ranges above easier to apply.

  • General wellness maintenance: monthly IV sessions at 250 to 500 mg, or SubQ injections at 100 to 200 mg 2 to 3 times weekly, paired with daily oral NMN (500 mg) or NR (300 mg).
  • Cognitive or acute energy support: a short IV loading series of 2 to 5 sessions at 500 to 750 mg, spaced every few days, with most people noticing subjective changes in mental clarity or fatigue within 1 to 2 weeks of the series.
  • Addiction recovery or neurology-focused intensive protocols: clinician-supervised daily IV dosing at 500 to 1,500 mg for 7 to 10 consecutive days, followed by a step-down to weekly or biweekly maintenance infusions. This tier absolutely requires direct medical supervision given the dose and duration involved.
  • Athletic recovery and performance support: daily oral precursor use timed around training cycles, with occasional IV sessions (250 to 500 mg) scheduled during heavier training blocks or after extended travel.

Some practitioners pair higher-dose precursor regimens with a methyl donor like TMG (trimethylglycine) to support the methylation pathways that heavy NMN or NR dosing can tax. It’s a detail worth raising with your clinician if you’re running the higher end of any oral range for an extended stretch.

What Safeguards Should a NAD+ Provider Have in Place?

A dosing chart is only as trustworthy as the clinical process behind it. Before starting any NAD+ protocol, the provider you choose should meet a few non-negotiable standards.

  • Full medical intake reviewed by a licensed clinician before anything gets prescribed, not a questionnaire that auto-approves.
  • Compounding at FDA-registered facilities following current good manufacturing practice standards, with purity testing on every batch.
  • Ongoing provider access, so dose adjustments happen based on how you’re actually responding, not on a fixed schedule set at intake.
  • Clear storage and handling guidance for compounded product delivered to your door, since reconstituted NAD+ has a shorter usable window than the lyophilized form.

Revive Meds builds its NAD+ protocols around exactly this structure: a full intake reviewed by a licensed clinician, medication compounded at FDA-registered US pharmacies with 99%+ purity testing, and unlimited messaging with your provider so dose changes reflect real feedback rather than guesswork. That follow-up loop matters clinically. NAD+ tolerance and response vary enough person to person that a static protocol handed out at intake and never revisited is a weaker standard of care than one that adjusts.

How NAD+ Dosing Interacts With Medications and Supplements

NAD+ therapy doesn’t exist in isolation from whatever else is in your medicine cabinet, and a few interactions deserve specific attention before you start.

PARP inhibitors, used in certain cancer treatments, compete with NAD+ for the same metabolic pathways, and combining them with NAD+ supplementation is generally avoided. Alcohol consumed heavily around infusion or injection times can compound the flushing and nausea some people already experience from NAD+ itself, so many clinicians suggest spacing them out.

Supplement stacking is where things get more nuanced. Niacin (vitamin B3) shares a metabolic pathway with NAD+ precursors, and taking high-dose niacin alongside NMN or NR can produce an intensified flushing reaction. Resveratrol is often paired with NAD+ precursors based on the theory that it activates sirtuin enzymes that use NAD+ as fuel, though the human evidence for that combination remains preliminary. Blood thinners and NAD+ therapy don’t have a well-documented direct interaction, but any new injectable or IV protocol should be disclosed to whoever manages your anticoagulation therapy, simply because bruising and injection-site reactions can complicate monitoring.

The safest approach is the boring one: bring your full medication and supplement list to your intake, and let your clinician flag anything that needs spacing out or dose adjustment before you start.

Health Conditions That Complicate NAD+ Dosing

Beyond the well-known contraindications of active cancer and pregnancy, several other health conditions change how a NAD+ protocol should be built.

Uncontrolled cardiovascular disease is a meaningful consideration, since the rate-dependent chest tightness and heart rate changes some patients experience during IV infusion can be harder to distinguish from a genuine cardiac event in someone with existing heart disease. Clinicians generally slow infusion rates significantly or avoid IV dosing altogether in this population.

Severe kidney or liver impairment affects how NAD+ metabolites and its precursors get cleared from the body, which can change both the effective dose and the risk of side effects. Autoimmune conditions, particularly those involving frequent infusion or injection therapies already, warrant extra caution around injection-site reactions and systemic inflammatory responses.

Breastfeeding carries the same caution as pregnancy, since NAD+ therapy hasn’t been studied in nursing mothers and there’s no established safety data to lean on. Severe allergy history, especially prior reactions to IV infusions of any kind, should push a provider toward starting with SubQ or oral dosing instead of jumping straight to IV. None of these conditions necessarily rule out NAD+ therapy entirely, but each one changes the starting dose, route, or monitoring plan your clinician should put in place.

IV vs SubQ vs Oral: Which Delivery Method Fits Your Life?

Dosing ranges tell only part of the story. The real difference between routes shows up in daily practicality.

IV delivery gives you the fastest, most complete bioavailability, since it bypasses digestion and the skin barrier entirely, but it ties you to a clinic chair for hours at a time and costs more per session than any other route. It’s the right tool when you need rapid repletion, not for indefinite weekly maintenance.

SubQ and IM injections split the difference. You get meaningfully better absorption than oral precursors without the time cost of an IV chair, and you can self-administer at home in under a minute once you’re comfortable with the technique. The trade-off is the injection itself: needle anxiety, site rotation, and managing the pain that comes with a concentrated subcutaneous dose.

Oral NMN and NR ask the least of you logistically, no needles, no clinic visits, just a capsule with breakfast, but they take longer to raise NAD+ levels and depend on consistent daily adherence to work. For someone who travels constantly or simply won’t stick with an injection routine, oral dosing may be the only protocol that actually gets followed, which matters more clinically than the theoretical bioavailability advantage of injectables.

Lab Tests and Biomarkers to Track NAD+ Therapy Progress

Dosing without measurement is just guessing with extra steps. A handful of labs and clinical markers give you and your clinician something concrete to track over time.

Direct blood NAD+ levels can be measured through specialty labs, though testing isn’t yet standardized or widely available at every clinic. More practically, many providers track NAD+ metabolite markers in blood or urine, which reflect how much of the precursor you’re taking is actually converting. Beyond direct NAD+ measures, clinicians often watch fasting glucose and lipid panels, since some patients on NAD+ therapy report metabolic shifts worth tracking over a few months. Basic metabolic panels, covering kidney and liver function, are worth rechecking periodically on higher-dose protocols simply because those organs handle clearance of the compound and its metabolites.

Subjective tracking matters just as much as lab values. Keeping a simple log of energy levels, sleep quality, and cognitive clarity on a 1 to 10 scale, checked weekly, gives your clinician real data to adjust dosing against, rather than a vague “I think it’s working.”

A Clinician’s View on Realistic NAD+ Dosing

Individualized dosing isn’t a marketing phrase, it’s the actual clinical reality of how differently people respond to the same milligram amount. Age, body weight, liver and kidney function, and even genetic variation in NAD+ metabolism all shift where someone’s effective starting dose lands. Two patients on an identical 100 mg SubQ protocol can report completely different experiences in week one.

Most patients notice subtle changes, better sleep, steadier energy, within 2 to 4 weeks of consistent dosing, with more pronounced shifts by 8 weeks. Anyone promising dramatic results in days is overselling. The protocols that actually hold up over time are the ones revisited every 4 to 8 weeks, with doses adjusted based on documented response rather than left on autopilot from day one.

— Amy

Getting Clinician-Guided NAD+ Dosing Without the Guesswork

Building a NAD+ protocol on your own from forum posts and clinic blogs is how people end up over-dosing an IV session or under-dosing a maintenance injection for months without knowing it. Revive Meds removes that gap by pairing every NAD+ prescription with a full medical intake reviewed by a licensed clinician, so your starting dose, route, and titration schedule reflect your actual health history instead of a generic chart.

Revive Meds

Every protocol is compounded at FDA-registered US pharmacies and tested for 99%+ purity, then delivered discreetly to your door in 48 to 72 hours, no clinic waiting room required. Once you start, unlimited provider messaging means dose adjustments happen based on how you’re actually responding at week two or week six, not a fixed schedule set once and forgotten. There’s no membership fee locking you in either way.

If you’re ready to move from researching ranges to getting an individualized protocol, start your medical intake for a personalized peptide protocol and a licensed clinician will review your history before anything ships.

Sources

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.